AstraZeneca PLC aims for $80 billion revenue by 2030 through strong growth in oncology, biopharmaceuticals, and rare diseases ...

It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good ...

AstraZeneca Plc is increasingly looking to the US for growth as its once fast-expanding China business faces challenges amid ...

The AstraZeneca (LSE:AZN) share price just dipped below £100 per share. The stock has seriously underperformed in recent months, falling from above £130 in August. So, let’s take a look at what’s ...

AstraZeneca (GB:AZN) has released an update. AstraZeneca’s Senior Independent Non-Executive Director, Philip Broadley, has made a notable ...

Astrazeneca has raised its guidance for the full year despite issues surrounding its presence in China according to today's ...

LONDON, Nov 12 (Reuters) - London-listed drugmaker AstraZeneca (AZN.L), opens new tab said its plan ... suggesting there is ...

BMO Capital Markets analyst Etzer Darout in a note to investors said the insurance fraud probe represents a “headline risk” ...

AstraZeneca's China president Leon Wang, who was detained last month by Chinese authorities, is in touch with a lawyer but ...

Profit after tax came in ₹38.4 crore in Q2 of FY25, a recovery from a net loss of ₹11.8 crore in the first quarter of this ...

The AstraZeneca (LSE: AZN) share price is in freefall at the moment. Yesterday (5 November), it fell 8.4%. Since late August, it has plummeted nearly 25%. So, what’s going on here? And has the share ...

Learn More. The AstraZeneca (LSE: AZN) share price is in freefall at the moment. Yesterday (5 November), it fell 8.4%. Since late August, it has plummeted nearly 25%. So, what’s going on here?